The price of Johnson & Johnson (NYSE:JNJ) shares last traded on Wall Street rose 0.11% to $177.01.
Based on available information, 22 analysts follow Johnson & Johnson (NYSE:JNJ). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $215.00 and a low of $160.00, we find $180.50. Given the previous closing price of $176.82, this indicates a potential upside of 2.08 percent. JNJ stock price is now 5.14% away from the 50-day moving average and 2.77% away from the 200-day moving average. The market capitalization of the company currently stands at $459.27B.
Among analysts, 14 rate the stock a hold while 6 rate it a buy. Brokers who have rated the stock have averaged $184.70 as their price target over the next twelve months.
With the price target of $170, Credit Suisse recently initiated with Neutral rating for Johnson & Johnson (NYSE: JNJ). On October 18, 2022, Barclays recently initiated its ‘Equal Weight’ rating on the stock quoting a target price of $175, while ‘BofA Securities’ rates the stock as ‘Neutral’.
In other news, Taubert Jennifer L, EVP, WW Chair, Pharmaceuticals sold 76,923 shares of the company’s stock on Nov 22. The stock was sold for $13,598,402 at an average price of $176.78. Upon completion of the transaction, the EVP, WW Chair, Pharmaceuticals now directly owns 126,456 shares in the company, valued at $22.38 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 18, Controller, CAO Decker Robert J sold 16,928 shares of the business’s stock. A total of $2,962,400 was realized by selling the stock at an average price of $175.00. This leaves the insider owning 15,473 shares of the company worth $2.74 million. Insiders disposed of 613,153 shares of company stock worth roughly $108.53 million over the past 1 year. A total of 0.09% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in JNJ stock. A new stake in Johnson & Johnson shares was purchased by AMALGAMATED FINANCIAL CORP. during the first quarter worth $127,942,000. TOMS CAPITAL INVESTMENT MANAGEMENT LP invested $83,874,000 in shares of JNJ during the first quarter. In the first quarter, CZECH NATIONAL BANK acquired a new stake in Johnson & Johnson valued at approximately $54,087,000. B&D WHITE CAPITAL COMPANY, LLC acquired a new stake in JNJ for approximately $27,135,000. RANDOLPH CO INC purchased a new stake in JNJ valued at around $26,933,000 in the second quarter. In total, there are 4,542 active investors with 70.80% ownership of the company’s stock.
A candlestick chart of Johnson & Johnson (NYSE: JNJ) showed a price of $176.44 on Wednesday morning. During the past 12 months, Johnson & Johnson has had a low of $155.72 and a high of $186.69. As of last week, the company has a debt-to-equity ratio of 0.43, a current ratio of 1.40, and a quick ratio of 1.20. The fifty day moving average price for JNJ is $168.60 and a two-hundred day moving average price translates $172.26 for the stock.
The latest earnings results from Johnson & Johnson (NYSE: JNJ) was released for Oct, 2022. According to the Drug Manufacturers – General Company, earnings per share came in at $2.55, beating analysts’ expectations of $2.47 by 0.08. This compares to $1.37 EPS in the same period last year. The net profit margin was 19.90% and return on equity was 25.60% for JNJ. The company reported revenue of $23.79 billion for the quarter, compared to $23.34 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.94 percent. For the current quarter, analysts expect JNJ to generate $23.91B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/06/2022. Investors who held shares on 11/22/2022 were paid a $1.13 dividend. On an annualized basis, this represents a $4.52 dividend and a 2.55% percent yield. There was an ex-dividend date of 11/21/2022 for this dividend. In terms of dividend payout ratio, JNJ is presently at 60.10%.
Johnson & Johnson(JNJ) Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company’s Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.